Bodycote Prices Break Risk, Not an 885p Proposal

Summary: BOY.UK closed at 831.5p on a source timestamp of 2026-05-22 17:29:00. Bodycote has confirmed a conditional proposal from Apollo Management X, L.P. for a possible all-cash offer at 885p per share, plus the proposed 2025 final dividend of 16.1p without reduction. That leaves the stock trading 6.0% below the cash offer price and 7.7% below the full 901.1p value stack, even after the company reported FY25 results that showed a stable core business, an £80 million new buyback, and a balance sheet with just 0.6x net debt/EBITDA. The board and Apollo are in discussions. Apollo has until June 19, 2026 to formalize or walk. The market is still pricing meaningful break risk into a named-bidder proposal with a four-week deadline. [1][2][3]

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	Bodycote prices break risk, not 885p	Europe / UK / industrials / possible offer	The stock trades 6.0% below Apollo's confirmed 885p cash proposal even after solid FY25 results, a new £80m buyback, and a board in active discussions with the bidder. The market still assigns meaningful probability to deal failure. [1][2][3]	Bodycote RNS dated May 22, 2026; FY25 results dated March 11, 2026; live quote checked in this run. [1][2][3]	Apollo must formalize or walk by June 19, 2026. [1]	Best mix of visible upside, near-dated catalyst, and liquid common-stock expression.	Selected.
2	Nippon Dry Chemical tender is live but the spread is gone	Japan / local-market equity / board-backed tender	ALSOK's tender for Nippon Dry Chemical is live at JPY 3,730 and the stock already trades at JPY 3,745 as of the May 21, 2026 Tokyo session. [4][5]	Official TDNet filings dated May 13, 2026; live quote checked in this run. [4][5]	Tender runs through June 29, 2026. [4]	Low. The spread has already inverted.	Rejected — no edge.
3	TIDLOR's dividend and buyback are real, but the stock already gapped hard	Broader Asia / Thailand / capital return / open-market buyback	TIDLOR approved a THB 0.69 interim dividend and a THB 2.4bn buyback for up to 4.24% of shares. The stock jumped to THB 17.60 by 10:27 a.m. Bangkok time on May 21, 2026. [6][7]	Official company release and same-day market coverage dated May 21, 2026. [6][7]	XD date June 2; buyback opens May 28. [6][7]	Moderate. The return stack is real.	The first-day gap already absorbed much of the easy rerating, and the buyback is still discretionary.
4	Expensify Dutch auction is live but upside is capped	U.S. / small-cap / modified Dutch auction	Expensify's tender range is $0.98–$1.20 and the stock trades at $1.14, leaving only 5.3% gross upside to the ceiling against meaningful downside if the tender clears at the low end. [8][9]	SEC Schedule TO dated May 13, 2026; live quote checked in this run. [8][9]	Tender expires June 10, 2026. [8]	Capped upside, binary clearing risk.	Rejected — risk/reward inferior to Bodycote.

Selected opportunity: Bodycote (BOY.UK).

Why this one now: It is the widest confirmed discount to a named-bidder cash proposal among the screened candidates, with the most near-dated hard catalyst and the strongest underlying business evidence.

What should surprise the reader: Bodycote's stock is still pricing in meaningful deal break risk even though the board is in active discussions with Apollo, the company just reported a stable core business with 0.6x leverage, and the bidder has a contractual deadline to formalize or walk within four weeks.

Geographic Search Audit

U.S. candidate screened: Expensify (EXFY.US). Rejected because the Dutch auction ceiling offers only 5.3% gross upside against meaningful downside. [8][9]
Japan candidate screened: Nippon Dry Chemical (1909.T). Rejected because the stock already trades above the offer price. [4][5]
Japan size / price filter result: The Japan lane first prioritized local small-cap and mid-cap names at or below JPY 800 per share. None surfaced in this run with a cleaner hard-value mismatch than the higher-priced tender names, so the lane was escalated and still rejected on spread quality.
Broader Asia candidate screened: TIDLOR. Rejected because the stock already gapped hard on the announcement and the repurchase is still discretionary. [6][7]
Europe / UK candidate screened: Bodycote (BOY.UK). Selected. [1][2][3]

Why This Is the Best Opportunity Right Now

Bodycote has already rallied on the Apollo news. The open was 709.5p. The close was 831.5p. That is a 17.2% intraday move. [3]

But the stock still sits 53.5p below the cash proposal. That is a 6.0% gap. Including the 16.1p final dividend, the full value stack is 901.1p. The stock trades 7.7% below that. [1][2][3]

The market is therefore still assigning meaningful probability to deal failure, even though:

Fact: on May 22, 2026, Bodycote confirmed it had received a conditional proposal from Apollo for a possible all-cash offer at 885p per share. The announcement was made under Rule 2.4 of the UK Takeover Code. The board and Apollo are in discussions. Apollo has until 5:00 p.m. on June 19, 2026 to announce a firm intention to make an offer or walk away. [1]

Fact: this was not Apollo's first approach. The announcement says the proposal follows "a number of previous proposals from Apollo to the Board." The parties are not starting from zero. [1]

Fact: on March 11, 2026, Bodycote reported FY25 results that were not spectacular but were stable. Core organic revenue was broadly flat (-0.3%). Core adjusted operating profit was £113.0m. The balance sheet ended the year with net debt of just £104.8m, or 0.6x EBITDA. The company announced a new £80m share buyback. [2]

The market is therefore still discounting a confirmed, named-bidder cash proposal for a company that is not in distress, has a strong balance sheet, and has a four-week deadline for the bidder to formalize.

That is the disagreement.

What Should Surprise the Reader

The surprise is not that deal risk exists. It does.

The surprise is that the market is still pricing a 6.0% discount to a named-bidder cash proposal after a 17% intraday rally on the news. The gap has closed, but it has not closed all the way.

A 6.0% spread to a cash proposal with a four-week deadline is not a large-arbitrage gap. But it is still a gap, and the evidence set does not obviously justify the remaining break-risk premium.

The Setup

Bodycote disclosed the proposal. The language is careful: Rule 2.4, not Rule 2.7. There is no certainty an offer will be made. The board did not say it recommends the proposal. It said discussions are ongoing. [1]

That is the bear case in one paragraph.

The bull case has more moving parts, but each one is grounded.

The bidder is real and has been persistent. Apollo made multiple previous approaches. This is not a one-shot expression of interest. [1]
The board is engaging. The announcement says the board and Apollo are in discussions. The board hired Barclays and Goldman Sachs as financial advisers. [1]
The business is stable. Core organic revenue was flat. Core adjusted operating profit was £113.0m. Margins compressed but the Optimise programme is delivering savings. The balance sheet is strong. [2]
The capital return programme is aggressive. Bodycote has repurchased £120m of shares since 2024 and just authorized another £80m. The board is not acting like it expects the stock to go to zero. [2]
The clock is short and binding. Apollo has until June 19 to formalize or walk. The market will get an answer in four weeks. [1]

The Market Price

Market Level	Current Reading	Source / Timestamp	Why It Matters
`BOY.UK` close	831.5p	Stooq quote feed, source timestamp 2026-05-22 17:29:00 [3]	Current entry reference.
`BOY.UK` open	709.5p	Same source [3]	Shows the pre-news baseline.
`BOY.UK` session high	833p	Same source [3]	The stock briefly touched above the close.
Apollo cash proposal	885p	Bodycote RNS, May 22, 2026 [1]	Hardest public number in the proposal.
Proposed final dividend	16.1p	Bodycote FY25 results, March 11, 2026 [2]	Retained by shareholders under the proposal.
Full value stack	901.1p	Author calculation from [1][2]	Cash plus dividend.
Discount to cash proposal	-6.0%	Author calculation from [1][3]	Shows how much failure risk the tape still assigns.
Discount to full stack	-7.7%	Author calculation from [1][2][3]	Best single expression of the disagreement.
FY25 core adjusted operating profit	£113.0m	Bodycote FY25 results [2]	Confirms the business is not in distress.
FY25 net debt / EBITDA	0.6x	Bodycote FY25 results [2]	Strong balance sheet, low leverage.
FY25 free cash flow	£47.5m	Bodycote FY25 results [2]	Supports dividend and buyback capacity.
New share buyback authorized	£80m	Bodycote FY25 results [2]	Board confidence signal.
Apollo deadline	June 19, 2026, 5:00 p.m.	Bodycote RNS [1]	The timing catalyst is explicit.

The Positioning

I did not verify live short interest, stock-loan cost, CDS, or listed-option skew for Bodycote in this run.

The positioning read here comes from the tape and the takeover code, not derivatives data.

The stock rallied 17% on the day but still closed below the proposal price. That means the market is assigning roughly a 6% break-risk premium to a named-bidder cash proposal with a four-week deadline. That is a real positioning signal even without borrow data.

Missing-data note: live borrow, short-interest, and listed-option-liquidity data were not fully verified in this run.

The Catalyst

This trade has a real clock.

June 19, 2026 deadline. Apollo must either announce a firm intention to make an offer under Rule 2.7 or announce it does not intend to make an offer. The Panel can extend this deadline, but only with consent. [1]
The board is already engaged. Discussions are ongoing. Financial advisers are in place. This is not a cold approach. [1]
The business has been refreshed. FY25 results are public. The market has the data it needs to assess stand-alone value. [2]

The key point is that this is not a "maybe someday" situation. The market gets an answer in four weeks.

The Gap

The market appears to believe that one or more of the following is true:

Apollo may never formalize the proposal.
If it does, the final terms may be worse than 885p.
Bodycote's results do not compel a bidder to pay up.
The Rule 2.4 disclosure without a board recommendation signals weak negotiations. [1]

Those are all reasonable concerns.

The non-consensus part is that the remaining 6.0% discount looks too wide relative to what has already been confirmed and the four-week deadline.

Facts:

a named bidder has been disclosed,
the public cash price has been disclosed,
discussions are ongoing,
the business just reported stable results with a strong balance sheet, and
the board authorized a new £80m buyback. [1][2]

Inference:

The market is still charging for a breakdown probability that may now be too high for the evidence set.

The Payoff Map

The cleanest expression is long Bodycote common stock.

This is not an options-first situation. I did not verify a live option chain with enough strike depth, open interest, and spread quality to recommend a derivative-led structure responsibly.

The thesis does not require a bidding war.

It requires one of two smaller things:

a firm offer near 885p, or
a reduction in the market's implied failure probability as the deadline approaches

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	885p	+6.4%	1 to 4 weeks	Apollo formalizes a firm offer at or near 885p and the market re-anchors to the cash price.	Medium
Base Case	40%	860p	+3.4%	1 to 6 weeks	Discussions continue constructively, the market gives more credit to the 885p cash leg, but still discounts full certainty.	Medium
Bottom Case	30%	760p	-8.6%	1 to 8 weeks	Apollo walks, delays without conviction, or signals materially weaker terms; the stock falls back toward stand-alone valuation.	Medium
Invalidation / Stop Condition	n/a	Sustained trade below 780p on company-specific evidence that talks are breaking or that the stand-alone outlook is deteriorating	n/a	Immediate once visible	The thesis fails when the public value stack stops being a live anchor.	Medium

Probability-weighted expected value: about 835p, or roughly +0.4% from the current market level. The edge is small at the current price. The trade is only attractive if the market continues to underprice the probability of a firm offer, or if the stock drifts lower on profit-taking, offering a better entry.

Current market price / level: BOY.UK 831.5p. [3]

Timestamp: source timestamp 2026-05-22 17:29:00. [3]

Primary instrument: Bodycote plc common stock.

Alternative expressions considered: waiting for a firm Rule 2.7 announcement; options. Waiting was rejected because much of the repricing could happen before formalization. Options were rejected because live chain quality was not responsibly verified in this run.

Confidence: Low. The edge is real but thin at the current price. A better entry may present itself on profit-taking or market noise.

What Could Go Wrong

The strongest counterargument is that the market is not confused at all.

It may simply be correctly pricing a conditional, board-disclosed, bidder-unsanctioned proposal that never becomes firm.

That is the most serious objection and it deserves weight.

Three more risks matter:

No board recommendation yet. The announcement was made under Rule 2.4, not Rule 2.7. The board has not recommended the proposal. That is unusual for a situation where the stock trades 6% below the offer price. [1]
Apollo may have reserved the right to worsen terms. The announcement does not rule out a lower price in certain circumstances. [1]
Stand-alone rerating may not save the trade quickly. Bodycote's results were stable, not explosive. Core margins compressed 160bps. If the bid disappears, the market may decide the business deserves a lower multiple even with the balance sheet intact. [2]

What Would Prove This Wrong

This thesis weakens materially if one of the following happens:

Apollo publicly walks before the market starts to re-anchor closer to stand-alone value. [1]
Bodycote signals that discussions have deteriorated or that an extension is being used to postpone a weaker outcome.
The company materially weakens its FY26 operating outlook beyond what was disclosed on March 11, 2026. [2]
The stock breaks and holds below 780p on company-specific news rather than on broad market noise.

Bottom Line

Bodycote has already rallied hard on the Apollo news. The open was 709.5p. The close was 831.5p. That is a 17% move. [3]

But the stock still trades 6.0% below the cash proposal. The market is still pricing meaningful break risk.

The edge is thin at the current price. The probability-weighted EV is only marginally positive. This is not a high-conviction situation. It is a short-dated, still-live event spread with a named bidder, a stable business, and a four-week clock.

The best version of this trade is to wait for a better entry on profit-taking or market noise, then express the view that the remaining break-risk premium is too high.

Best trade strategy: Long Bodycote common stock on weakness. Options are not the lead instrument here.

Research Quality Scorecard

Criterion	Score	Evidence Note
Market disagreement	4	The note isolates a visible 6.0% gap between the live market price and a confirmed named-bidder cash proposal. The gap is real but thinner than the initial open-price read suggested.
Evidence base	5	Core claims rely on Bodycote's own Rule 2.4 RNS, Bodycote's FY25 results release, and a current quote check.
Positioning and flows	3	The tape clearly shows the market still assigns meaningful break risk, but live borrow and short-interest data were not verified.
Catalyst path	5	The June 19, 2026 deadline under the UK Takeover Code is explicit and near-dated.
Payoff architecture	3	Upside is tied to a known cash price but the edge is thin at the current price. Downside is bounded by a stable stand-alone business.
Invalidation discipline	4	The thesis breaks on observable evidence of a walk-away, weaker terms, or worsening stand-alone guidance.
Differentiated insight	4	The non-obvious point is that the market is still pricing meaningful break risk after a 17% intraday rally on the news.
Client value	5	The note helps readers separate proposal quality, disclosure quality, and stand-alone business quality even without taking the trade.

Total Score: 33 / 40

Verdict: Publish

AI Illustration Prompt

A realistic, high-value, high-end editorial cover image for The Mispricing Desk about Bodycote in May 2026. Show a quiet, expensive industrial boardroom at dusk with a polished dark table. On one side, place a crisp white offer document stamped 885p CASH and a smaller card reading 16.1p FINAL DIVIDEND — RETAINED, together forming 901.1p. On the other side, place a glowing market price ticket reading 831.5p, closer to the offer than before but still visibly below it, as if traders have priced in most but not all of the good news. Through large windows, hint at a Bodycote heat-treatment plant at night with warm orange glow from furnaces, blending industrial reality with boardroom tension. Add a discreet desk calendar turned to 19 JUNE 2026 and a faint note reading Rule 2.4 — discussions ongoing to capture the central risk. Mood: tense, institutional, premium, forensic. Palette: charcoal, midnight blue, warm furnace orange, brushed steel, and parchment white. No cliché stock charts, no giant arrows, no cartoon money. Make it feel like a Bloomberg Markets or Economist deal-feature cover. Include a subtle but clear watermark or text treatment reading The Mispricing Desk.

Sources

[1] Bodycote plc — Response to media speculation, Rule 2.4 announcement, published May 22, 2026

[2] Bodycote plc — 2025 Full Year Results, published March 11, 2026

[3] Stooq quote feed for BOY.UK, checked in this run

[4] ALSOK / TCG2511 Inc. TDNet notice commencing tender offer for Nippon Dry Chemical, published May 13, 2026

[5] Stooq quote feed for 1909.JP, checked in this run

[6] TIDLOR Announces 0.69 Baht Interim Dividend and 2.4 Billion Baht Share Repurchase, published May 21, 2026

[7] Kaohoon International coverage showing TIDLOR at THB 17.60 at 10:27 a.m. Bangkok time on May 21, 2026

[8] Expensify, Inc. — Modified Dutch Auction Tender Offer, SEC Schedule TO, filed May 13, 2026

[9] Stooq quote feed for EXFY.US, checked in this run